ELVN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $36,684,325.08

Enliven Therapeutics Insider Trading History Chart

Enliven Therapeutics Share Price & Price History

^$20.74

▲ +0.45 (2.22%)

As of 03/14/2025 05:00 PM ET

Days: 30 | 90 | 365

Enliven Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2025	Anish Patel	COO	Sell	6,667	$21.44	$142,940.48	323,310
2/27/2025	Benjamin Hohl	CFO	Sell	3,250	$20.41	$66,332.50	13,000
2/7/2025	Anish Patel	COO	Sell	6,667	$21.93	$146,207.31	329,977
2/5/2025	Benjamin Hohl	CFO	Sell	1,000	$22.52	$22,520.00	13,000
1/27/2025	Benjamin Hohl	CFO	Sell	3,250	$21.59	$70,167.50	13,000
1/7/2025	Anish Patel	COO	Sell	21,700	$24.18	$524,706.00
1/3/2025	Benjamin Hohl	CFO	Sell	1,000	$25.04	$25,040.00	13,000
12/30/2024	Benjamin Hohl	CFO	Sell	900	$22.51	$20,259.00
12/27/2024	Benjamin Hohl	CFO	Sell	3,350	$22.15	$74,202.50
11/27/2024	Benjamin Hohl	CFO	Sell	5,250	$24.89	$130,672.50
10/28/2024	Benjamin Hohl	CFO	Sell	6,250	$28.56	$178,500.00
10/18/2024	Anish Patel	COO	Sell	716	$30.00	$21,480.00	343,311
10/18/2024	Benjamin Hohl	CFO	Sell	814	$30.00	$24,420.00
10/18/2024	Joseph P Lyssikatos	Insider	Sell	847	$30.00	$25,410.00	1,015,188
10/18/2024	Richard A Heyman	Director	Sell	817	$30.00	$24,510.00	123,673
10/18/2024	Samuel Kintz	CEO	Sell	924	$30.00	$27,720.00	1,002,892
10/15/2024	Richard A Heyman	Director	Sell	1,270	$27.67	$35,140.90	124,490
10/9/2024	Joseph P Lyssikatos	Insider	Sell	37,878	$28.16	$1,066,644.48	1,016,035
10/9/2024	Samuel Kintz	CEO	Sell	16,710	$28.15	$470,386.50	1,003,816
10/8/2024	Rahul D Ballal	Director	Sell	10,420	$28.17	$293,531.40	22,341
10/7/2024	Benjamin Hohl	CFO	Sell	1,270	$27.51	$34,937.70
10/7/2024	Joseph P Lyssikatos	Insider	Sell	2,707	$27.61	$74,740.27	1,067,180
10/7/2024	Samuel Kintz	CEO	Sell	2,730	$27.50	$75,075.00	1,033,793
10/4/2024	Benjamin Hohl	CFO	Sell	10,218	$27.51	$281,097.18
10/4/2024	Joseph P Lyssikatos	Insider	Sell	7,522	$27.51	$206,930.22	1,069,887
10/4/2024	Richard A Heyman	Director	Sell	2,825	$27.51	$77,715.75	125,760
10/4/2024	Samuel Kintz	CEO	Sell	12,206	$27.51	$335,787.06	1,036,523
10/1/2024	Joseph P Lyssikatos	Insider	Sell	527	$27.54	$14,513.58	1,077,409
10/1/2024	Richard A Heyman	Director	Sell	518	$27.54	$14,265.72	128,585
10/1/2024	Samuel Kintz	CEO	Sell	526	$27.54	$14,486.04	1,048,729
9/30/2024	Benjamin Hohl	CFO	Sell	2,000	$25.33	$50,660.00
9/27/2024	Benjamin Hohl	CFO	Sell	4,250	$24.27	$103,147.50
8/29/2024	Joseph P Lyssikatos	Insider	Sell	12,000	$22.49	$269,880.00	1,077,936
8/27/2024	Benjamin Hohl	CFO	Sell	4,250	$22.54	$95,795.00
8/26/2024	Samuel Kintz	CEO	Sell	12,000	$22.89	$274,680.00	1,049,255
8/15/2024	Richard A Heyman	Director	Sell	1,270	$23.25	$29,527.50	130,373
7/31/2024	Benjamin Hohl	CFO	Sell	991	$27.53	$27,282.23
7/31/2024	Joseph P Lyssikatos	Insider	Sell	3,099	$27.56	$85,408.44	1,089,936
7/31/2024	Richard A Heyman	Director	Sell	1,702	$27.51	$46,822.02	131,643
7/31/2024	Samuel Kintz	CEO	Sell	2,270	$27.56	$62,561.20	1,061,255
7/29/2024	Benjamin Hohl	CFO	Sell	5,250	$26.68	$140,070.00
7/29/2024	Joseph P Lyssikatos	Insider	Sell	12,000	$26.70	$320,400.00	1,093,035
7/25/2024	Samuel Kintz	CEO	Sell	12,000	$24.92	$299,040.00	1,063,525
7/15/2024	Anish Patel	COO	Sell	30,978	$25.05	$775,998.90	345,574
7/15/2024	Richard A Heyman	Director	Sell	1,270	$24.80	$31,496.00	133,345
7/12/2024	Anish Patel	COO	Sell	17,475	$25.07	$438,098.25	376,552
7/12/2024	Benjamin Hohl	CFO	Sell	3,000	$25.07	$75,210.00
6/27/2024	Benjamin Hohl	CFO	Sell	4,250	$22.57	$95,922.50
6/25/2024	Samuel Kintz	CEO	Sell	12,000	$21.66	$259,920.00	1,075,525
6/6/2024	Anish Patel	COO	Sell	1,133	$20.06	$22,727.98
5/28/2024	Benjamin Hohl	CFO	Sell	4,250	$23.18	$98,515.00
5/28/2024	Samuel Kintz	CEO	Sell	12,000	$23.18	$278,160.00
5/16/2024	Rishi Gupta	Director	Sell	1,033,300	$22.14	$22,877,262.00	254,814
5/14/2024	Anish Patel	COO	Sell	1,107	$25.00	$27,675.00
5/9/2024	Anish Patel	COO	Sell	260	$25.06	$6,515.60
5/6/2024	Anish Patel	COO	Sell	4,875	$22.72	$110,760.00
5/3/2024	Benjamin Hohl	CFO	Sell	1,000	$22.50	$22,500.00
4/29/2024	Benjamin Hohl	CFO	Sell	3,250	$16.97	$55,152.50
4/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$17.92	$215,040.00
4/25/2024	Samuel Kintz	CEO	Sell	12,000	$16.89	$202,680.00
4/15/2024	Richard A Heyman	Director	Sell	1,270	$19.99	$25,387.30	137,155
4/11/2024	Anish Patel	COO	Sell	17,500	$25.03	$438,025.00
4/11/2024	Benjamin Hohl	CFO	Sell	14,000	$24.72	$346,080.00
4/11/2024	Joseph P. Lyssikatos	insider	Sell	30,000	$25.04	$751,200.00
4/11/2024	Rahul D Ballal	Director	Sell	53,400	$23.95	$1,278,930.00	22,341
4/11/2024	Samuel Kintz	CEO	Sell	47,709	$25.04	$1,194,633.36
4/8/2024	Anish Patel	COO	Sell	4,875	$18.60	$90,675.00	2,597
4/4/2024	Rahul D Ballal	Director	Sell	3,485	$19.15	$66,737.75	22,341
4/1/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$18.60	$223,200.00
4/1/2024	Rahul D Ballal	Director	Sell	3,237	$19.08	$61,761.96	22,341
3/27/2024	Benjamin Hohl	CFO	Sell	3,250	$18.25	$59,312.50
3/25/2024	Samuel Kintz	CEO	Sell	12,000	$17.56	$210,720.00
3/19/2024	Richard A Heyman	Director	Sell	1,270	$14.50	$18,415.00	143,470
3/6/2024	Anish Patel	COO	Sell	4,875	$15.64	$76,245.00	7,472
2/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$16.42	$197,040.00
2/27/2024	Benjamin Hohl	CFO	Sell	3,250	$16.97	$55,152.50
2/15/2024	Richard A Heyman	Director	Sell	1,270	$17.42	$22,123.40	144,740
2/6/2024	Anish Patel	COO	Sell	4,875	$15.11	$73,661.25	12,347
1/31/2024	5Am Partners Vi, Llc	Major Shareholder	Sell	500,000	$15.00	$7,500,000.00	771,983
1/30/2024	Richard A Heyman	Director	Sell	1,270	$16.41	$20,840.70	146,010
1/29/2024	Benjamin Hohl	CFO	Sell	3,250	$15.81	$51,382.50
1/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$15.85	$190,200.00
1/25/2024	Samuel Kintz	CEO	Sell	12,000	$15.69	$188,280.00
1/22/2024	Anish Patel	COO	Sell	4,875	$15.13	$73,758.75	17,222
1/2/2024	Anish Patel	COO	Sell	11,000	$15.00	$165,000.00	22,097
1/2/2024	Benjamin Hohl	CFO	Sell	9,383	$15.01	$140,838.83
12/26/2023	Anish Patel	COO	Sell	102	$15.01	$1,531.02	35,637
12/26/2023	Benjamin Hohl	CFO	Sell	100	$15.00	$1,500.00
12/26/2023	Samuel Kintz	CEO	Sell	12,000	$14.64	$175,680.00
12/22/2023	Anish Patel	COO	Sell	983	$15.03	$14,774.49	35,739
12/22/2023	Benjamin Hohl	CFO	Sell	1,030	$15.07	$15,522.10
12/22/2023	Samuel Kintz	CEO	Sell	8,175	$13.05	$106,683.75
12/21/2023	Joseph P. Lyssikatos	insider	Sell	20	$13.00	$260.00
12/21/2023	Richard A Heyman	Director	Sell	7	$13.00	$91.00	147,448
12/20/2023	Samuel Kintz	CEO	Sell	7,779	$13.01	$101,204.79
12/19/2023	Joseph P. Lyssikatos	insider	Sell	200	$13.00	$2,600.00
12/19/2023	Richard A Heyman	Director	Sell	255	$13.00	$3,315.00	149,565
11/3/2023	Joseph P. Lyssikatos	insider	Sell	8,546	$13.08	$111,781.68
11/3/2023	Samuel Kintz	CEO	Sell	8,026	$13.08	$104,980.08
9/29/2023	Joseph P. Lyssikatos	insider	Sell	12,000	$13.62	$163,440.00
9/26/2023	5Am Partners Vi, Llc	Major Shareholder	Sell	197,500	$15.00	$2,962,500.00	854,796
9/25/2023	Samuel Kintz	CEO	Sell	12,000	$13.81	$165,720.00
8/24/2023	5Am Partners Vi, Llc	Major Shareholder	Sell	440,000	$16.00	$7,040,000.00	887,507

SEC Filings (Institutional Ownership Changes) for Enliven Therapeutics (NASDAQ:ELVN)

95.08% of Enliven Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Enliven Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	43,714	$0.98M	0.0%	+67.1%	0.089%
2/17/2025	Soleus Capital Management L.P.	75,405	$1.70M	0.1%	-68.5%	0.154%
2/17/2025	Two Sigma Investments LP	14,620	$0.33M	0.0%	-33.8%	0.030%
2/17/2025	Stempoint Capital LP	96,716	$2.18M	0.5%	N/A	0.198%
2/17/2025	Polar Capital Holdings Plc	2,389,668	$53.77M	0.3%	+267.6%	4.891%
2/17/2025	ProShare Advisors LLC	12,229	$0.28M	0.0%	+29.5%	0.025%
2/17/2025	Patient Square Capital LP	224,038	$5.04M	1.9%	+147.4%	0.459%
2/17/2025	Nicholas Investment Partners LP	157,635	$3.55M	0.3%	-9.3%	0.323%
2/17/2025	Millennium Management LLC	50,804	$1.14M	0.0%	+108.6%	0.104%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	20,036	$0.45M	0.0%	+3.7%	0.041%
2/17/2025	Janus Henderson Group PLC	1,331,877	$30M	0.0%	+27.9%	2.726%
2/17/2025	Graham Capital Management L.P.	15,178	$0.34M	0.0%	+67.3%	0.031%
2/17/2025	Deutsche Bank AG	30,516	$0.69M	0.0%	+51.7%	0.062%
2/17/2025	Brevan Howard Capital Management LP	10,144	$0.23M	0.0%	N/A	0.021%
2/17/2025	Bank of America Corp DE	34,187	$0.77M	0.0%	-29.8%	0.070%
2/17/2025	BNP Paribas Financial Markets	4,991	$0.11M	0.0%	N/A	0.010%
2/17/2025	Ameriprise Financial Inc.	35,059	$0.79M	0.0%	N/A	0.072%
2/17/2025	Ally Bridge Group NY LLC	141,710	$3.19M	2.7%	-39.7%	0.290%
2/17/2025	5AM Venture Management LLC	1,629,765	$36.67M	8.8%	-7.0%	3.336%
2/17/2025	Acuta Capital Partners LLC	267,368	$6.02M	6.1%	-9.8%	0.547%
2/14/2025	Boxer Capital Management LLC	671,358	$15.11M	1.3%	N/A	1.374%
2/14/2025	RA Capital Management L.P.	848,986	$19.10M	0.3%	-20.0%	1.738%
2/14/2025	Northern Trust Corp	331,500	$7.46M	0.0%	+8.9%	0.678%
2/14/2025	Artia Global Partners LP	102,900	$2.32M	0.8%	N/A	0.211%
2/14/2025	Boothbay Fund Management LLC	104,890	$2.36M	0.1%	-21.0%	0.215%
2/14/2025	Virtus ETF Advisers LLC	3,091	$70K	0.0%	-26.2%	0.006%
2/14/2025	Lord Abbett & CO. LLC	386,211	$8.69M	0.0%	+20.3%	0.790%
2/14/2025	Voya Investment Management LLC	10,702	$0.24M	0.0%	-8.1%	0.022%
2/14/2025	Adage Capital Partners GP L.L.C.	650,000	$14.63M	0.0%	-18.8%	1.330%
2/14/2025	Price T Rowe Associates Inc. MD	13,627	$0.31M	0.0%	+17.0%	0.028%
2/14/2025	Tower Research Capital LLC TRC	1,598	$36K	0.0%	+230.2%	0.003%
2/14/2025	MetLife Investment Management LLC	21,746	$0.49M	0.0%	+6.3%	0.045%
2/13/2025	Marshall Wace LLP	41,382	$0.93M	0.0%	-70.0%	0.085%
2/13/2025	Barclays PLC	64,563	$1.45M	0.0%	+14.8%	0.132%
2/13/2025	Legal & General Group Plc	21,140	$0.48M	0.0%	-2.9%	0.043%
2/13/2025	Invesco Ltd.	15,072	$0.34M	0.0%	+3.5%	0.031%
2/13/2025	FMR LLC	6,495,871	$146.16M	0.0%	+3.2%	13.295%
2/13/2025	Federated Hermes Inc.	117,552	$2.65M	0.0%	N/A	0.241%
2/13/2025	Wells Fargo & Company MN	16,666	$0.38M	0.0%	+49.9%	0.034%
2/12/2025	ExodusPoint Capital Management LP	8,900	$0.20M	0.0%	N/A	0.018%
2/12/2025	Geode Capital Management LLC	762,718	$17.17M	0.0%	+1.7%	1.561%
2/12/2025	Wellington Management Group LLP	80,916	$1.82M	0.0%	+15.3%	0.166%
2/12/2025	Pictet Asset Management Holding SA	972,293	$21.88M	0.0%	+16.3%	1.990%
2/12/2025	JPMorgan Chase & Co.	19,745	$0.44M	0.0%	-5.1%	0.040%
2/11/2025	Corebridge Financial Inc.	17,500	$0.39M	0.0%	-7.0%	0.036%
2/11/2025	Vanguard Group Inc.	1,975,655	$44.45M	0.0%	+2.9%	4.044%
2/11/2025	KLP Kapitalforvaltning AS	4,300	$97K	0.0%	N/A	0.009%
2/11/2025	Intech Investment Management LLC	16,322	$0.37M	0.0%	N/A	0.033%
2/10/2025	Swiss National Bank	41,873	$0.94M	0.0%	+13.9%	0.086%
2/6/2025	Charles Schwab Investment Management Inc.	261,888	$5.89M	0.0%	+2.6%	0.536%
2/4/2025	Bank of New York Mellon Corp	89,575	$2.02M	0.0%	-0.9%	0.183%
1/31/2025	New York State Common Retirement Fund	25,023	$0.56M	0.0%	-9.0%	0.051%
1/29/2025	Legato Capital Management LLC	13,492	$0.30M	0.0%	-7.5%	0.028%
1/24/2025	China Universal Asset Management Co. Ltd.	10,360	$0.23M	0.0%	+14.0%	0.021%
1/17/2025	SG Americas Securities LLC	16,629	$0.37M	0.0%	+66.1%	0.034%
12/13/2024	Lord Abbett & CO. LLC	321,055	$8.20M	0.0%	N/A	0.657%
11/27/2024	Franklin Resources Inc.	20,151	$0.56M	0.0%	N/A	0.041%
11/19/2024	Barclays PLC	56,217	$1.44M	0.0%	+295.8%	0.115%
11/16/2024	Geode Capital Management LLC	750,208	$19.16M	0.0%	+9.9%	1.588%
11/15/2024	Barclays PLC	56,217	$1.44M	0.0%	+295.8%	0.119%
11/15/2024	Jane Street Group LLC	30,793	$0.79M	0.0%	-41.9%	0.065%
11/15/2024	Wellington Management Group LLP	70,170	$1.79M	0.0%	+107.0%	0.149%
11/15/2024	State Street Corp	745,944	$19.05M	0.0%	+2.9%	1.579%
11/15/2024	RA Capital Management L.P.	1,061,233	$27.10M	0.3%	-50.0%	2.246%
11/15/2024	Patient Square Capital LP	90,572	$2.31M	0.9%	N/A	0.192%
11/15/2024	Ikarian Capital LLC	499,566	$12.76M	1.7%	-14.8%	1.058%
11/15/2024	Janus Henderson Group PLC	1,041,724	$26.61M	0.0%	+43.0%	2.205%
11/15/2024	HighVista Strategies LLC	112,459	$2.87M	1.0%	-6.1%	0.238%
11/14/2024	Verition Fund Management LLC	10,610	$0.27M	0.0%	N/A	0.022%
11/14/2024	Walleye Capital LLC	99,416	$2.54M	0.0%	N/A	0.210%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	26,168	$0.67M	0.0%	+12.7%	0.055%
11/14/2024	Ally Bridge Group NY LLC	234,856	$6M	3.2%	N/A	0.497%
11/14/2024	Acuta Capital Partners LLC	296,368	$7.57M	6.1%	-25.5%	0.627%
11/13/2024	FMR LLC	6,296,179	$160.80M	0.0%	+10.6%	13.328%
11/13/2024	The Manufacturers Life Insurance Company	17,282	$0.44M	0.0%	+25.6%	0.037%
11/12/2024	Charles Schwab Investment Management Inc.	255,277	$6.52M	0.0%	+10.4%	0.540%
11/7/2024	First Turn Management LLC	535,092	$13.67M	2.2%	+29.5%	1.133%
11/7/2024	Quest Partners LLC	21,117	$0.54M	0.0%	+1,226.4%	0.045%
10/25/2024	China Universal Asset Management Co. Ltd.	9,085	$0.23M	0.0%	+64.4%	0.019%
10/10/2024	Exchange Traded Concepts LLC	7,483	$0.19M	0.0%	-60.3%	0.016%
10/3/2024	SG Americas Securities LLC	10,013	$0.26M	0.0%	N/A	0.021%
8/15/2024	The Manufacturers Life Insurance Company	13,764	$0.32M	0.0%	N/A	0.029%
8/14/2024	Marshall Wace LLP	192,100	$4.49M	0.0%	N/A	0.408%
8/14/2024	Logos Global Management LP	595,000	$13.91M	1.1%	-62.2%	1.265%
8/14/2024	HighVista Strategies LLC	119,789	$2.80M	1.0%	-5.6%	0.255%
8/8/2024	First Turn Management LLC	413,243	$9.66M	1.6%	N/A	0.879%
8/8/2024	Nicholas Investment Partners LP	56,072	$1.31M	0.1%	N/A	0.119%
8/8/2024	American Century Companies Inc.	27,651	$0.65M	0.0%	+44.7%	0.059%
8/6/2024	Quest Partners LLC	1,592	$37K	0.0%	+87.3%	0.003%
8/1/2024	Rhumbline Advisers	49,627	$1.16M	0.0%	+29.9%	0.105%
7/26/2024	Bank of New York Mellon Corp	114,109	$2.67M	0.0%	+49.2%	0.243%
5/16/2024	California State Teachers Retirement System	19,141	$0.34M	0.0%	-5.8%	0.041%
5/16/2024	Janus Henderson Group PLC	713,911	$12.60M	0.0%	+74.8%	1.519%
5/16/2024	Blackstone Inc.	25,191	$0.44M	0.0%	N/A	0.054%
5/15/2024	Baker BROS. Advisors LP	114,833	$2.02M	0.0%	N/A	0.244%
5/14/2024	EntryPoint Capital LLC	9,510	$0.17M	0.1%	N/A	0.020%
5/10/2024	Vanguard Group Inc.	1,183,266	$20.81M	0.0%	-3.9%	2.517%
5/7/2024	SG Americas Securities LLC	9,430	$0.17M	0.0%	-30.2%	0.020%
4/29/2024	China Universal Asset Management Co. Ltd.	7,952	$0.14M	0.0%	+67.0%	0.017%
2/13/2024	Tower Research Capital LLC TRC	5,485	$76K	0.0%	-18.8%	0.013%

Data available starting January 2016

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $20.74

$20.55

$22.21

50 Day Range

MA: $21.59

$19.62

$24.15

52 Week Range

Now: $20.74

$10.90

$30.03

Volume

205,365 shs

Average Volume

230,869 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Who are the company insiders with the largest holdings of Enliven Therapeutics?: Enliven Therapeutics' top insider investors include:
Joseph P Lyssikatos (Insider)
Samuel Kintz (CEO)
5Am Partners Vi, Llc (Major Shareholder)
Anish Patel (COO)
Rishi Gupta (Director)
Richard A Heyman (Director)
Rahul D Ballal (Director)
Benjamin Hohl (CFO)
Joseph P Lyssikatos (Insider)
Learn More about top insider investors at Enliven Therapeutics.
Who are the major institutional investors of Enliven Therapeutics?: Enliven Therapeutics' top institutional shareholders include:
FMR LLC — 13.29%
Polar Capital Holdings Plc — 4.89%
Vanguard Group Inc. — 4.04%
5AM Venture Management LLC — 3.34%
Janus Henderson Group PLC — 2.73%
Pictet Asset Management Holding SA — 1.99%
Learn More about top institutional investors of Enliven Therapeutics stock.
Which institutional investors are selling Enliven Therapeutics stock?: Within the previous quarter, ELVN stock was sold by these institutional investors:
RA Capital Management L.P.
Soleus Capital Management L.P.
Adage Capital Partners GP L.L.C.
5AM Venture Management LLC
Marshall Wace LLP
Ally Bridge Group NY LLC
Acuta Capital Partners LLC
Boothbay Fund Management LLC
In the previous year, company insiders that have sold Enliven Therapeutics company stock include:
Joseph P Lyssikatos (Insider)
Samuel Kintz (CEO)
5Am Partners Vi, Llc (Major Shareholder)
Anish Patel (COO)
Rishi Gupta (Director)
Richard A Heyman (Director)
Rahul D Ballal (Director)
Benjamin Hohl (CFO)
Learn More investors selling Enliven Therapeutics stock.
Which institutional investors are buying Enliven Therapeutics stock?: During the previous quarter, ELVN stock was acquired by institutional investors including:
Polar Capital Holdings Plc
Boxer Capital Management LLC
Janus Henderson Group PLC
FMR LLC
Pictet Asset Management Holding SA
Patient Square Capital LP
Federated Hermes Inc.
Artia Global Partners LP